This inventor holds 1 USPTO granted patent. Top assignees: Children's Medical Center Corporation, Massachusetts Institute of Technology. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2018
Title: Michael J Webber: Innovator in Diabetes Treatment
Introduction
Michael J Webber is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of diabetes treatment through his innovative research and development of insulin derivatives. His work focuses on creating compounds and methods that enhance the delivery of therapeutic agents, particularly insulin.
Latest Patents
Michael J Webber holds 1 patent for his groundbreaking work titled "Insulin derivatives for diabetes treatment." This patent describes compounds, compositions, and methods for the 'smart' delivery of insulin through glucose-sensing insulin derivatives. These derivatives are designed to bind serum albumin or agglomerate in vivo, effectively dissociating to release insulin in hyperglycemic conditions. The innovative approach allows for self-regulated and long-term diabetes management, providing a significant advancement in diabetes care.
Career Highlights
Throughout his career, Michael has worked with esteemed institutions such as the Massachusetts Institute of Technology and Children's Medical Center Corporation. His research has been pivotal in developing new strategies for diabetes management, showcasing his commitment to improving patient outcomes.
Collaborations
Michael has collaborated with notable individuals in his field, including Benjamin C Tang and Daniel Griffith Anderson. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Michael J Webber's innovative work in diabetes treatment exemplifies the impact of research and development in healthcare. His contributions continue to pave the way for improved management of diabetes through advanced therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile